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This project will present the molecular modeling of hyaluronic acid (HA), cisplatin, 
polylactic-co-glycolic acid (PLGA) and PEG-his amine as uni-molecular modeling 
and also conjugated forms of multi-molecular modeling for targeted delivery to 
cancer cells in 3D format by using Discovery Studios 2.5 software from Accelrys 
Inc. USA. Colorectal cancer cell will be the case study for targeted drug delivery. 
The methodologies to be used include molecular modeling design are molecular 
modeling, model development of cisplatin, PLGA, and HA. The simulation studies 
on drug delivery to colorectal cancer cells of the bioconjugated forms of the 
compounds will also be carried on. 
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1.1 BACKGROUND OF STUDY 
Cancer is one of the major disease that causes 13% of all human deaths in 2007 
(Gul-e-Saba, et al., 2010) Cancer is a class of diseases in which a group of cells 
display uncontrolled growth, invasion that intrudes upon and destroys adjacent 
tissues and sometimes spreading to other locations in the body via lymph or blood 
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Figurel.l How cancer starts (Cancer Council, 2011) 
Malignant or 
invasive cancer 
Chemotherapy is standard treatment of most disseminated cancers, but dose-limiting 
toxicities and the emergence of cancer cells resistant to chemotherapeutic drugs 
often reduce the clinical benefit (Chen et al., 2007) Cisplatin is one of the most 
effective chemotherapeutic agents against many forms of cancer including testicular, 
bladder, head and neck, ovarian, breast, lung, prostate, and refractory non-Hodgkin ' s 
lymphomas (Jamieson & Lippard, 1999; Rosenberg et al., 1969). Indeed, cisplatin is 
used to treat 50% of all cancers (Galanski et al. , 2005), and it exerts its antitumor 
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effects by disrupting DNA structure in cell nuclei through the formation of 
intrastrand and interstrand cross-links (Wang & Lippard, 2005). 
The development of drug delivery systems has improved the therapeutic and 
toxicological properties of existing chemotherapies and facilitated the 
implementation of new ones. By including the drug in technologically optimized 
drug delivery systems or conjugating the drugs with different polymers, it is possible 
to modify the pharmacokinetics and biodistribution of the drugs improving the 
efficacy and security of the therapy (Peppas & Blanchette, 2004). 
Nanoparticulate delivery systems, such as those based on poly (lactic-co-glycolic 
acid) (PLGA) polymers, have been studied extensively for many years. PLGA 
polymers have the advantage of being well characterized and already commercial! y 
used for microparticulate drug delivery systems (Ailemann & Leroux, 1999) PLGA 
polymers are biocompatible, biodegradable, and bio-resorbable (Wise et a!., 1979). 
Natural and synthetic polymers including albumin, fibrinogen, alginate, chitosan, 
and collagen have been used for the fabrication of nanoparticles. However, among 
all of these, lactic-glycolic acid copolymers are the most frequently employed 
materials due to their biocompatibility and biodegradability (Orive et a!., 2005) 
Hyaluronic acid (HA) is a glycosaminoglycan found distributed throughout the 
connective, epithelial and neural tissues (Laurent et a!., 1995). It is one of the main 
components of the extracellular matrix, contributes significantly to cell proliferation 
and migration and is also involved in the progression of some malignant tumors 
where it is highly concentrated. Besides, it turns out to be an important signal for 
activating kinase pathways (Misra et a!., 2006; Ohno et a!., 2006) and regulating 
angiogenesis (Rooney et a!., 1995). The physiological function of HA varies greatly 
depending on HA size, and the presence or absence of HA binding proteins and cell 
surface receptors (Tammi et a!., 2002; Toole, 2004). Many tumors are enriched in 
HA (Tammi eta!., 2002; Boregowda eta!., 2006). HA levels can be increased within 
the tumor cells themselves or within the tumoral stroma (Anttila et a!., 2000; 
Auvinen et a!., 2000). 
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The advanced tool that could help drug developers are in the use of computational 
modelling for designing, testing and simulating the molecular structure of the drugs. 
Drug modelling helps to better understand the interactions of drug with 
microenvironment in the body at the disease sites. In this study, hyaluronic acid 
contaning cisplatin-loaded polylagtic-co-glycolic acid bioconjugates as a potential 
anticancer drug will be modelled and simulated for targeted delivery to cancer cells. 
1.2 PROBLEM STATEMENT 
Designing the molecular structure of the vehicle contains drug by 
computational approach could be the best solution as it provides better 
understanding of effective delivery, drug accumulation in cancer cells, reduce the 
experimental cost , trial failure and save time. 
1.3 OBJECTIVES 
1. To model 3-D Uni-Molecular modeling of Hyaluronic Acid (HA), Cisplatin , 
Polylactic-co-glycolic acid and Multi-molecular modeling of Cisplatin, PLGA, 
PEG, HA and conjugated molecular 3D Structures PLGA conjugated HA 
,cisplatin conjugated HA and PLGA-PEG-HA conjugates. Detail Inter and 
Intra-molecular measurement of Bond length with bond order and type of bond 
were also discussed. 
2. To simulate the controlled, targeted drug delivery system of the Hyaluronic 
Acid (HA) containing Cisplatin-loaded PLGA nanosphere bioconjugates. 
3 
1.4 SCOPE OF STUDY 
The project will cover molecular modeling of Hyaluronic Acid (HA) containing 
Cisplatin-loaded PLGA nanosphere bioconjugates as an anti-cancer drug for 
controlled, targeted delivery to cancer cells. The Discovery Studio 2.5 (Accelrys 





2.1 COLORECTAL CANCER 
Colorectal cancer is cancer that starts in the colon or the rectum. These cancers can 
also be referred to separately as colon cancer or rectal cancer, depending on where 
they start. The colon and rectum together make up the large intestine, part of the 
body's digestive system. The colon is a large muscular tube (approximately five feet 
long) that collects and stores waste which then passes into the rectum. Tumors can 
develop within the walls of the colon and/or rectum tissue which are called polyps 
(American Cancer Society, 2005) (Figure 2.1). 
Figure 2.1 Colorectal in human body (www.fitcare.net, 2009) 
Colorectal cancer is one of the most common tumors and a major cause of cancer 
death worldwide (Fiore et al., 2007). Recent studies from the Cancer incidence in 
five continents volume IX have shown an increasing incidence of colorectal cancer 
in Asian populations. According to the Second Report of the National Cancer 
Registry, colorectal cancers accounted for 14.2% of male cancers and 10.1% of 
female cancers in Malaysia, making it the commonest cancers among men and the 
third most common cancer among women respectively. The incidence of colon 
cancer in Chinese was 2 times higher compared to other ethnic groups (Figure 2.2). 
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Colorectal cancer 1s the third commonest cause of cancer-related mortality m 
Malaysia. 




Figure 2.2 Colorectal Cancer Cases(%) per 100,000 Populations by Ethnic Group 
(Norsidawati, 2009) 
These tumors can either be malignant (cancerous) or benign. Benign polyps may 
develop into adenomatous polyps over time and infact, about 85% of all colorectal 
cancers develop fromadenomatous polyps (American Cancer Society, 2005). There 
are 5 stages in the development of colorectal cancer (Figure 2.3). 
Figure 2.3 Colorectal Cancer stages (National Cancer Institute) 
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Stage 0: this is the earliest stage, the cancer is found only in the innermost of the 
colon 
Stage I: the cancer starts to evolves in the inner wall of the colon 
Stage II: the cancer become bigger and spread outside the colon but not yet to the 
lymph nodes (Lymph nodes are smal~ bean-shaped structures that are part of the 
body's immune system.) 
Stage III: the cancer spreads nearby the lymph nodes but not to the other parts of the 
body 
Stage IV: the cancer has spread to the other part of the body such liver and lungs, 
this is the most serious stage of the colo rectal cancer (Adapted from National Cancer 
Institute). 
Several types of cancer can start in the colon or rectum. More than 95% of colorectal 
cancers are a type of cancer known as Adenocarcinomas. These cancers start in 
cells that form glands that make mucus to lubricate the inside of the colon and 
rectum. Other, less common types of tumors may also start in the colon and rectum. 
These include Carcinoid tumors. These tumors start from specialized hormone-
producing cells in the intestine. Gastrointestinal stromal tumors (GISTs) start 
from specialized cells in the wall of the colon called the interstitial cells of Cajal. 
Some are benign (noncancerous); others are malignant (cancerous). These tumors 
can be found anywhere in the digestive tract, but they are unusual in the colon. 
Lymphomas are cancers of immune system cells that typically start in lymph nodes, 
but they may also start in the colon, rectum, or other organs. Sarcomas can start in 
blood vessels as well as in muscle and connective tissue in the wall of the colon and 
rectum. Sarcomas of the colon or rectum are rare. (Adapted from American cancer 
society) 
2.2 CISPLATIN AS ANTI-CANCER DRUG 
The biological activity of cisplatin, was discovered serendipitously about 125 years 
after the initial report of its synthesis and characterization. Although the synthesis 
and characterization of cisplatin was first reported by Peyrone in 1845 (Peyrone, 
1845), its anticancer properties remained unnoticed until the mid-1960s, when 
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Rosenberg and co-workers studied the effects of electric fields on Escherichia coli 
growth (Rosenberg et a!., 1965). The great impact in the treatment of cancer of the 
platinum coordination complex cisplatin, [ cis-diamminedichloro platinum(II)] or cis-
DDP, is a paradigm within the use of metals in medicine. In fact, cisplatin and its 
analogue carboplatin, [ cis-diammine-1, 1-cyclobutanedicarboxylate platinum( II)] are 
among the most commonly used antitumor drugs today Tumor resistance to cis-DDP 
coupled with cisplatin toxicity have stimulated the search for other antitumor-active 
platinum complexes with improved pharmacological properties. The only registered 
platinum drug that has consistently demonstrated antitumor activity against cisplatin 
resistant tumors such as colorectal cancers is oxaliplatin, [trans-L-1,2-
diaminocyclohexaneoxalatoplatinum(II)] (Cvitkovic,1998). (Fig. 2.4 depicts the 
structures of the three platinum antitumor drugs currently approved for clinical use 
by both the American Food and Drug administration (FDA) and the European 
Agency for the Evaluation of Medicinal Products (EMEA) as well as the structure of 
the inactive isomer of cisplatin, transplatin (trans-DDP)). 
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Figure 2.4 (A) cisplatin, (B) carboplatin, (C) oxaliplatin and (D) biologically 
inactive transplatin. (Cepeda et al., 2007)) 
The mechanism of anticancer activity involves formation of platinum- DNA adducts 
that are capable of inhibiting DNA and RNA synthesis (Johnson eta!., 1989). and 
inducing programmed cell death (Barry et al.,1990; Ormerod eta!., 1996). Cisplatin 
binds preferentially to the N7 position of purine residues. The monofunctional 
adduct subsequently closes to a bifunctional adduct by linking a second purine that 
can be either of the same strand or of the opposite strand (Sherman & Lippard, 
1987). There is general consensus that the antitumor efficacy of cisplatin is 
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(d) 
associated with the formation of DNA 1,2-intrastrand d(GpG) or d(ApG) cross-links 
(Lippert et all. ,1984). The 1,2-intrastrand crosslinks locally unwind and bend 
doublestranded DNA toward the major groove (Takahara et al., 1995,; Takahara et 
al., 1996, Rice et al., 1988), and the disturbance of DNA secondary structure seems 
to be the ultimate reason for inhibition of DNA replication and/or transcription and 
for triggering apoptotic cell death (Sorenson et al ., 1990, Barri et al., 1990). 
A B 
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Figure 2.5 Main adducts formed after binding of cis-DDP to DNA. (A) 1,2-
intrastrand cross-link, (B) interstrand cross-link, (C) monofunctional adduct, and (D) 
protein-DNA cross-link. The main site of attack of cis-DDP to DNA (N7 of guanine) 
is shown in the central panel. (Cepeda et al., 2007) 
Cisplatin is one of the most potent anticancer agents available today and is widely 
used in the treatment of many malignancies, including testicular, ovarian, bladder, 
head and neck, small cell and non-small cell lung cancers (Comis, 1994) and 
(Boulikas & Vougiouka, 2004). However, its use is associated with severe side 
effects, such as acute nephrotoxicity and chronic neurotoxicity (Ponzani et al., 1994). 
A more selective administration (targeting) of cisplatin to cancer cells would reduce 
drug toxicity and enhance its therapeutic potential. Passive targeting of anticancer 
drugs to tumors could be achieved by attaching them to long circulating soluble or 
particulate carriers taking advantage of the enhanced permeability and retention 
(EPR) effect. The EPR effect is a result of leaky capillaries adjacent to solid tumors 
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and a lack of a lymphatic system for the drainage of drugs back to the systemic 
circulation (Kwon, 1998). The association of drugs with long-circulating carriers 
alters drug pharmacokinetics and results in increased drug accumulation in tumors, 
based on the EPR effect. For a more selective delivery to tumors, cisplatin has been 
administered in the form of soluble drug-polymer conjugates (Avichezer et al., 
1998; Fenuti et al., 1999 Malik et al., 1999) and (Gianasi et al., 1999), or in the form 
of colloidal carriers, such as pegylated liposomes (Newman et al., 1999), 
poly(aspartic) acid-poly(ethylene glycol) micelles (Nishiyama et al., 2011), and 
poly( caprolactone)-poly( ethylene glycol) or poly( caprolactone)-poly[2-(N,N-
dimethylamino)ethyl methacrylate] micelles (Van Kirk et a!., 2006)(Figure 2 6 The 
example of design and construction of nanoparticles by PLGA-PEG polymer with 
the cisplatin-bearing polymer (PLA-cisplatin). 
Design •nd Construction of N•nopartldes 
.................... ...,..,._._. .......... cOOH + ~
I'I.GA KG Po1ymH I'I.A <nplobn 
0 Cl>piMW\ De<NMI A !llolo<ulor ~ 
loty* .... llcOn.<)l ~OrvtJ 
Figure 2.6 PLGA-PEG polymer with the cisplatin-bearmg polymer (PLA-cisplatin). 
Oocetaxel is then added to the mix. As nanoparticles self-assemble, docetaxel is 
encapsulated inside. In the final step, a molecular tag is added to enable the particle 
to navigate itself to the target of interest (PNAS, 2010) 
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2.3 PLGA AS A DRUG DELIVERY AGENT 
The development of drug delivery systems has improved the therapeutic and 
toxicological properties of existing chemotherapies and facilitated the 
implementation of new ones. By including the drug in technologically optimized 
drug delivery systems or conjugating the drugs with different polymers, it is possible 
to modify the pharmacokinetics and biodistribution of the drugs improving the 
efficacy and security of the therapy (Peppas & Blanchette, 2004). 
Recent developments in nanotechnology have allowed new research strategies to 
flourish in the field of drug delivery. There has been considerable interest in 
developing nanoparticles as effective drug delivery carriers (Allemann et al. , 
1993)(Figure 2. 7). 
Figure 2.7 Advantage ofNanocarriers (Nanoparticles as nano-carriers can increase 
solubility, stability, specificity, multimodality, and efficacy, while reducing toxic 
side effects and improving upon the non-specificity of conventionally delivered 
cancer treatments) (Shaker et al. , 2011). 
A critical advantage in treating cancer with advanced, non-solution based therapies is 
the inherent leaky vasculature present serving cancerous tissues. The defective 
vascular architecture, created due to the rapid vascularization necessary to serve fast 
growing cancers, coupled with poor lymphatic drainage allows an enhanced 
permeation and retention effect (EPR effect) (Teicher, 2000; Sledge & Miller, 2003). 
Targeting the tumor vasculature is a strategy that can allow targeted delivery to a 
wide range of tumor types (Eatock et al., 2000; Reynolds et al. , 2003).Tremendous 
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opportunities exist for using nanoparticles as controlled drug delivery systems for 
cancer treatment (Panyam & Labhasetwar, 2003; Birnham & Branno-Peppas, 2004). 
Natural and synthetic polymers including albumin, fibrinogen, alginate, chitosan, 
and collagen have been used for the fabrication of nanoparticles. However, among 
all of these, lactic-glycolic acid copolymers are the most frequently employed 
materials due to their biocompatibility and biodegradability (Orive et al., 2005). 
Nanoparticulate delivery systems, such as those based on poly(lactic-co-glycolic 
acid) (PLGA)(Figure 2.8 Shows structure of PLGA) polymers, have been studied 
extensively for many years. PLGA polymers have the advantage of being well 
characterized and already commercially used for microparticulate drug delivery 
systems (Allemann et al., 1999). The PLGA polymer had several advantages like 
good mechanical properties, low immunogenicity and toxicity, excellent 
biocompatibility and predictable biodegradation kinetics. The wide acceptance of the 
lactide/glycolide polymers as suture materials made them attractive candidates for 
biomedical applications like ligament reconstruction, tracheal replacement, surgical 
dressings, vascular grafts and nerve, dental and fracture repairs (Lewis, 1990; 
Visscher et a!., 1988). Polymeric nanoparticles of this polymer are used for the 
delivery of various drugs ( antipsychotics, anesthetics, antibiotics, antiparasites, 
anti tum orals, hormones, proteins, etc) (Verger et al., 1998). Drug carriers must show 
persistence in systemic circulation after intravenous administration in order to be 
useful for controlled drug delivery and/ or targeting applications. The biodistribution 
properties of polylactide-coglycolide- co-polyethylene glycol (PLGA-PEG) 
nanoparticles have been studied in experimental animals after labeling them with 
radioactive agents. The results showed a character of extending half-life and ability 
to control the release of the encapsulated compounds (Li et al., 2001). PLGA-PEG 
nanoparticles were found to exhibit linear, dose-independent pharmacokinetics for a 
dose range of 150-1050 f-Ig per mouse. The dosage-independence of the PLGA-PEG 
nanoparticles would provide further advantages for their application in controlled 
drug delivery and targeting (Beletsi eta!., 2005). PLGA nanoparticles can be formed 
by interfacial deposition following solvent displacement technique (Fessi et a!., 
1989). Several compounds such as indomethacin (Cauchetier et a!., 2003) and 
muramyl dipeptide MDB-B305 (Barichello et a!., 1999) have been incorporated in 
this tech-nique. 
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Figure 2.8 Chemical structure of poly (glycolic acid) (PGA), poly (lactic acid) 
(PLA), and poly (lactic-co-glycolic acid) (PLGA) (Ikada et al., 2000) 
The use of polyethylene glycol is one of the most common practices for passive 
targeting to the tumor site. A biocompatible and biodegradable nanoparticulate 
system using long circulating PLGA-monomethoxy-poly (polyethylene glycol) 
(PLGA-mPEG) nanoparticles has been synthesized (Avgoustakis et al., 2003). The 
main advantage of this nanoparticulate system, encapsulating cisplatin, is its 
potential for passive cancer targeting. Cisplatin-doped PLGA-mPEG nanoparticles 
showed an initial rapid release of drug, followed by a relatively slow release phase in 
vitro at a pH of7.4, as shown by most PLGA-based nanoparticles. However, it was 
observed that the release kinetics depend on the ratio of PLGA to mPEG. The 
amount of released cisplatin in the initial burst increases with the increase of the 
amount of mPEG in the nanoformulation. Intravenous administration in BALB/c 
mice of this nanoformulation incorporating cisplatin resulted in an increased 
cisplatin residence time in the systemic circulation (Avgoustakis et al., 2003). The 
comparative cytotoxic effects of cisplatin were demonstrated when encapsulated in 
PLGA-mPEG nanoparticles on human prostate cancer LNCaP vs. free cisplatin 
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Figure 2.9 Representation of the Pt-PLGA-b-PEG-Apt-NP construct. Chemical 
structure of the Pt (IV) prodrug 1 and intracellular reduction for the release of active 
cisplatin in PSMA expressing human prostate cancer LNCaP cells after receptor 
mediated endocytosis ofPt-PLGA-b-PEG-Apt-NP (Dhar et al., 2011) 
2.4 HYALURONIC-ACID CONTAINING BIOCONJUGA TES 
Hyaluronic acid (HA) is a repeating disaccharide units composed of D-glucuronic 
acid and N-acetyl-D-glucosamine and can be considered as the main component of 
the extracellular matrix of the cell membrane and plays an important role in the 
mechanical support of the cell of many tissues such as the skin, the tendons, the 
muscles and cartilage (Mohapatra, et al , 2008). (Fig 2 I 0 shows the structure of an 
HA). 
OH OH 0~({ HO~({ 0 HQ~O~ 
0~ n 
Figure 2.10 Structure of an HA (www.anikatherapeutics.com , access 2011) 
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HA can interact with CD44, its receptor at the cell surface which can lead to the site-
specific delivery or targeted delivery of the drug (Yadav et al. , 2010). This case on 
degrade inside the cells (Luo et al. , 2009). The modeling development will include 
HA, which can be encapsulated and formulated with various peptide, PLGA and 
small molecular drugs ( cisplatin) for cell specific drug delivery. The nanoparticles 
are basically from natural polymers, biocompatibles and biodegradables. The PLGA 
allow the controlled release of the active molecules they transport which is anti-
cancer drug and their orientation towards the target tissues (Mohapatra, et al. , 2008). 
Targeting of anti-cancer agents to tumor cells and tumor metastases can be 
accomplished by receptor-mediated uptake of bioconjugates of anti-cancer agents 
conjugated to HA, followed by the release of free drugs through the degradation of 
HA in cell compartments (Luo, et al., 2009)(Figure 2.11 Shows interaction of HA-
drug with CD44 receptors on tumor cell) (Figure 2.12 Synthesis and release of RA-
Pt conjugates). 
a b c 
Figure 2.11 Interaction of HA-drug with CD44 receptors on tumour cell (a), cell 
absorbs molecule by engulfing it through the CD44 "door" (b), HA-drug degrades 
and drug is released directly into the key areas of the cell (e.g. lysosomes), causing it 
to die (c)( DiMeo et al., 2007,2008). 
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Figure 2.12 Synthesis and release ofHA-Pt conjugates (Surg, 2009). 
Hyaluronan or HA an important molecule (glycosaminoglycan) found almost 
everywhere in the human body shows a selective interaction with a specific cellular 
receptor, the CD44, which is over-expressed in many cancers. By the linkage of an 
anticancer drug on the HA chain, a more selective target and release of the 
chemotherapeutic agent to tumour cells can be achieved (Di Meo C. et a!., 2007, 
2008; Platt V. M. et a!., 2008) (Figure 2.11 ). 
Ligand Binding ----+ 
Re-gion 





Figure 2.13 Schematic representation ofCD44 molecule (Gul-e-Saba et al., 2010) 
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2.5 POLY (ETHYLENE GLYCOL)- PEG 
PEG is the common abbreviation for polyethylene glycol - or, more properly, 
poly (ethylene glycol) which refers to a chemical compound composed of repeating 
ethylene glycol units 
Poly( ethylene glycol) has several chemical properties that make it especially useful 
in various biological, chemical and pharmaceutical settings. 
• Non-toxic and non-immunogenic - can be added to media and attached to 
surfaces and conjugated to molecules without interfering with cellular 
functions or target immunogenicities 
• Hydrophilic (aqueous-soluble) - attachment to proteins and other 
biomolecules decreases aggregation and increases solubility 
• Highly flexible - provides for surface treatment or bioconjugation without 




3.1 RESEARCH METHODOLOGY 
The study has been divided into 2 phases for FYP I and FYP II as follows: 
3.1.1 FYP I PROJECT ACTIVITIES 
The uni-molecular modeling had been modeled separately usmg Discovery 














C ondtmcn anrl 
dllcumon 
HA 
Figure 3.1 FYP 1 Project activities (Research on molecular modeling of cisplatin 
PLGA and HA and the uni-molecular modeling had been modeled) 
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r-------------------------------------- -------------------------
The 3D modeling of anticancer agent (Cisplatin) 
The study chose Cisplatin to be modeled (refer to Fig.2.4) and the 
following shows its modeling instruction: 
1) Discovery Studios 2.5 was opened by using its software icon on the 
desktop. 
2) Molecule window was opened from menu File I New I Molecule 
Window. 
3) The Draw Tool was selected from Sketching Toolbar. 
4) The Platinum atoms was drawn as the center atom, the lower left 
atom( Chlorine) was clicked then the mouse was dragged to lower left 
and single click was pressed after that to make a new atom and by 
clicking on the new atom, it released the cursor. Then, the upper left 
atom (Chlorine) was clicked and the mouse was dragged to upper left 




5) The upper and lower bond of Nitrogen was drawn by using the 
previous method. The 3 hydrogen atom was drawn by dragged 3 
hydrogen from Nitrogen atom. 
6) Optimizing the geometry of the structure was needed since the 
drawing model was not yet precise and accurate in terms of standard 
bond length, bond angles and Van der Waals radii for close contact. 
The Clean Geometry was chose from Chemistry Toolbar; this can be 
clicked repeatedly until there's no longer changing in the model. 
7) Annotation to the model was needed by choosing Annotation Tool in 
Sketching Toolbar and left clicking on the place where to put the 
annotation then the word 'Cisplatin' was typed in the dialog box and 
finally the 'OK' button was pressed. 
----------------------------------------------------------------
Figure 3.2 Instruction of generate a 3D uni- molecular modeling of 
Cisplatin The completed model of Cisplatin PLGA PEG-his-amine (as 
spacer arm ofPLGA conjugated HA) and HA has illustrated in the next 
chapter (Fig 4.1, 4.2, 4.3, and 4.4). 
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3.1.2 FYP II PROJECT ACTIVITIES 
Multi-molecular modeling of Cisplatin-HA, PLGA-PEG-HA and Cisplatin-PLGA-
PEG-HA had been modeled. Instruction of generate these conjugated molecules is by 
making a bond linked between those molecules. The bond length and basic 










Figure 3.3 FYP 2 project activities (Multi-molecular modeling had been modeled by 
using Discovery Studios 2.5 (Accelrys Inc., USA)) 
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3.2 TOOLS REQUIREMENT 
Tools requirement as for development of the molecular modeling are shown below. 
• Discovery Studios 2.5 (Accelrys Inc., USA) 
fill ldot 'iJMf g..,odry :itruclln s.m-co Chtrt Sou>ts ytndow ~ 
t~ U (J } X ., , t< ~ + ~ ~ :•: "a: .I 4 ' >- 0 eo 
F1loc Tool; Ptolocok X 
- E!l Oiscovwy 511.<110 
+ 2J AOMET 
• :J Cont .. N llano 
+ :.) EloctroNtct 
• :) Gonotll 1'\rpooe 
• .J La ory ~~no~ys,. 
• ~ Laory 0..11111 
• 21 Plla'II\ICOIIIlar• 
+ :..;) Ptow .. Madl:.,. 
+ 1J OSAR 
• :..;) Race!>tcr-L,...d ht•octoans; 
+ .!) Sequon:e Anotys .. 
+ :..;) S11nu"'han 
• :!) X-toy 
0 .-·a protocols 
t lcoiN to 
Discovery Studio 2. 5 
Solutions for Computational Chemistry and Biology 
Welcome to Oscovery S!!Jdo& 2.S. i suu or l<'e soence PJ!tw¥e s<*i':JOns nd.ld.,g toot for prot en. II 
modelnQ. To get JOlted, use ::>e fololW>O H.! to btcom!! ,...... "''-" ;.'It softwo<e 111d !ilo usefu nf 
Quick Tours View Sdml)le files Help 
s.r-- 1 n 1723lli69943 
Figure 3.4 User interface ofDiscovery Studios 2.5 (Accelrys Inc., USA). 
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3.3 PROJECf TIMELINE 
W1 Wl W3 W4 ws W6 W7 WI W9 w w w w w w w w 
Activities in FYP I 10 11 u u 14 15 16 17 1SIS 12/S Z!lt'S S/6 1Z/6 l!lf6 Z616 ln 11n '1.417 ltn 718 1418 '1.118 '1.tll 419 1119 
Selection of project topic 
Preliminary research work 
a) Literature revtew: Modeling of HA 
I I 
I 
containing Cisplatin-loaded PLGA 
nanosphere bioconjugates for targeted 
delivery to cancer cells ..:.:: ..:.:: $ $ 
~ ~ 
Submission of extended proposal D ..:.:: c I c ~ C> C> 
~ ·.:::: ·.:::: 
~ ' = = 
Proposal defense I I ..... .51 .51 
-o e e 
.a = a 00. ~ Project work continues ~ 
"; -;, 
b) Execute the uni-molecular modeling I I .51 .51 i ~ ~ 
c) Execute the multi-molecular modeling I u 'I i I I 
I 
Submission of Interim Draft ~eport I I I ~ 
I 
I 
Submission of Interim Report c 
I 
--- --- -----·-
Table 3.1 : Final Year Project I (May 2011) proposed activities timeline. 
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Adivides ill FYP D Wl W2 W3 •• W5 ., W7 ... W9 Wll Wll wu Wll WI• W15 WM Wl7 
:1619 .1111 I WII 17111 WII ,)1/11 7111 lolfll 21111 2&'11 M2 12112 IWI2 Wl2 .JI/12 WI 1611 
Project work continues 
[J\';'~. . ,, 
-.••• h r. ~~ d;,_' ' c_l 
D 
Project work contmues 
f) Report writing: discussion, I I conclusion and recommendations ...:.: ...:.: ~ ~ 
D ~ ~ Pre-EDX ...:.: = = ~ e 0 ·.: ".C 
D ~ Gil Gil Submission ofDraft .... .e .e ., e i 
.a Gil 
D 00 ~ " Submission of Dissertation (soft ~-; 'iJ bound .e .e 
r. r. 
Submission of Technical D 
Oral Presentation 
Submission of Dissertation (hard 
bound 
Table 3.2: Fmal Year Project II (September 2011 ) proposed activities timeline. 
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CHAPTER4 
RESULTS AND DISCUSSION 
4.1 MOLECULAR MODELING 
The following content illustrate the molecular modelmg developed by using Discovery 
Studios 2.5 (Accelrys Inc., USA) 
4.1.1 Uni-molecular Modeling 
Fig. 4.1, 4.2, 4.3 and 4.4 show uni-molecular structure of cisplatm, a carrier molecule 
(PLGA), Poly( ethylene glycol) bis(amme) - PEG and Hyaluronic acid (HA) respectively 
Detail bond length amongst the atoms of these uni-molecular modeling are shown in 
Table 4.1, 4.2, 4.3 and 4.4 respectively. 







Figure 4.1 Molecular modeling of Cisplatin with each atom numbered. 
Table 4.1: Baste properties of cisplatm 
No. Molecular Molecular Molecular Exact 
of formula composition weight molecular 
atoms weight 






Table 4.2: Bond and length of cisplatin 
No Name Parent Order Type Length 
1 N1- Pt2 Cisplatin 1 Single 2.00447 
2 Pt2- Cl3 Cisplatin 1 Single 2.30153 
3 Pt2- Cl4 Cisplatin 1 Single 2.30062 




1.02963 -5 N5 -H6 1 Single 
6 N5 -H7 Cisplatin 1 I Single 1.02998 
7 N5 -H8 Cisplatin 1 Single 1.02946 
- -- -
8 Nl -H9 Cisplatin 1 Single 1.02944 
9 Nl- HIO Cisplatin 1 Single 1.02941 
10 Nl- Hll Cisplatin 1 Single 1.0297 
Figure 4.1 shows modeling of Cisplatin with each atom numbered. Cisplatin structure 
shows the total measurements of bond length =11 with average bond length = 
1.478765. The table 4.1 shows modeling of Cisplatin the total number of atom is 11 with 
molecular composition Cl: 0.236, H: 0.020, N: 0 093, Pt: 0.650 and net formal charge =0. 
Name 
PLGA 







Figure 4.2 Molecular modeling of PLGA 
Table 4.3: Basic properties ofPLGA 
Molecular Molecular Molecular 





C: 0.405, H: 0.054, 
- r- -







Table 4.4: Bond and length ofPLGA 
No Name Pal'ent Order Type Length 
1 01- C2 PLGA 1 Single 1.42944 
2 C2- C3 PLGA 1 Single 1.50007 
3 C3- 04 PLGA I Single 1.40999 
4 04- C5 PLGA 1 Single 1.44509 
5 C5- C6 PLGA 1 Single 1.5004 
6 C3- 07 PLGA 2 Double 1.23722 
7 C5- C8 PLGA 1 Single 1.55092 
8 C6- 09 PLGA 2 Double 1.23615 
9 01 -HI PLGA 1 Single 1.05003 
10 C2-H2 PLGA 1 Single 1.09 
11 C2-H3 PLGA 1 Single 1.09 
12 C5 -H4 PLGA 1 Single 1.09 
13 C6-H5 PLGA 1 Single 1.09 
14 C8-H6 PLGA 1 Single 1.08996 
15 C8-H7 PLGA 1 Single 1.09003 
16 C8-H8 PLGA 1 Single 1.09003 
Figure 4.2 shows modeling of PLGA with each atom numbered. PLGA structure shows 
the total measurements of bond length= 16 with average bond length = 1.249333.The 
table 4.3 shows modeling of PLGA, the total number of atom is 18 with molecular 
composition C: 0.405, H: 0.054, 0 : 0.540 and net formal charge =0. 
(3) Poly(ethylene glycol) bis(amine) - PEG 
2 
Figure 4.3 Molecular modeling of Poly( ethylene glycol) bis(amine) - PEG 
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Table 4.5: Basic properties ofPoly(ethylene glycol) bis(amine) 
No. Exact Net Molecular Molecular Molecular Name of molecular formal formula composition weight 
atoms weight charge 
Poly( ethylene C4H12 C: 0.461, H: glycol) 19 N20 0.116, N: 0.269, 104.154 104.095 0 bis(amine) 0: 0.154 
Table 4.6: Bond and length ofPoly(ethylene glycol) bis(amine)-PEG 
No Name Parent Order Type Length 
1 N1-C2 Poly( ethylene glycol) bis(amine) 1 Single 1.46616 
2 C2-C3 Poly( ethylene glycol) bis(amine) 1 Single 1.53352 
3 C3- 04 Poly( ethylene glycol) bis(amine) 1 Single 1.42302 
4 04- C5 Poly( ethylene glycol) bis(amine) 1 Single 1.42302 
5 C5- C6 Poly( ethylene glycol) bis(amine) 1 Single 1.53352 
6 C6- N7 Poly( ethylene glycol) bis(amine) 1 Single 1.46616 
7 N1- H1 Poly( ethylene glycol) bis(amine) 1 Single 1.02949 
8 N1-H2 Poly( ethylene glycol) bis(amine) 1 Single 1.02949 
9 C2-H3 Poly( ethylene glycol) bis(amine) 1 Single 1.09939 
10 C2-H4 Poly( ethylene glycol) bis(amine) 1 Single 1.09939 
11 C3 -H5 Poly( ethylene glycol) bis(amine) I Single 1.09913 
12 C3 -H6 Poly( ethylene glycol) bis(amine) 1 Single 1.09913 
13 C5 -H7 Poly( ethylene glycol) bis(amine) 1 Single 1.09913 
14 C5 -H8 Poly( ethylene glycol) bis(amine) 1 Single 1.09913 
15 C6-H9 Poly( ethylene glycol) bis(amine) 1 Single 1.09939 
16 C6- H10 Poly( ethylene glycoQ bis(amine) 1 Single 1.09939 
17 N7 -Hll Poly( ethylene glycol) bis(amine) 1 Single 1.02949 
18 N7 -Hl2 Poly( ethylene glycol) bis(amine) 1 Single 1.02949 
Figure 4.3 shows modeling of Poly( ethylene glycol) bis(amine)- PEG with each atom 
numbered. PLGA structure shows the total measurements of bond length = 18 with 
average bond length = 1.208747.The table 4.5 shows modeling of PLGA, the total 
number of atom is 18 with molecular composition C: 0.461, H: 0.116, N: 0.269, 0: 
0.154and net formal charge =0. 
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( 4) Hyaluronic acid {HA) 
Figure 4.4 Hyaluronic acid (HA) 
Table 4.7: Basic properties of Hyaluronic acid 
No. of Molecular Molecular Molecular Name 
atoms formula composition weight 









Table 4.8: Bond and length of Hyaluronic acid(HA) 
No Name Parent Order Typ_e Leng!_h 
1 C1- C2 Hyaluronic Acid 1 Single 1.59635 
~ --C2- C3 Hyaluronic Acid 1 Single 1.4931 
3 C3- C4 Hyaluronic Acid 1 Single 1.59474 
4 C4- 05 Hyaluronic Acid 1 Single 1.48098 
5 05- C6 Hyaluronic Acid 1 Single 1.38242 
6 C6- Cl Hyaluronic Acid 1 Single 1.55595 
7 C6- C7 Hyaluronic Acid 1 Single 1.50029 
8 C7- 08 Hyaluronic Acid 2 Double 1.23601 
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No Name Parent Order Type Length 
9 C7- 09 Hyaluronic Acid 1 Single 1.39077 
10 Cl- 010 Hyaluronic Acid 1 Single 1.4566 
11 010- Cll Hyaluronic Acid 1 Single 1.43783 
12 C2- 012 Hyaluronic Acid 1 Single 1.42998 
13 C3- 013 Hyaluronic Acid 1 Single 1.42868 
14 C4- 014 Hyaluronic Acid 1 Single 1.45673 
15 014- C15 Hyaluronic Acid 1 Single 1.45659 
16 CIS- C16 Hyaluronic Acid 1 Single 1.49247 
17 C16- C17 Hyaluronic Acid 1 Single 1.60289 
18 C17- 018 Hyaluronic Acid 1 Single 1.4804 
19 018- C19 Hyaluronic Acid 1 Single 1.37854 
20 C19- C20 Hyaluronic Acid 1 Single 1.56016 
21 C20- C15 Hyaluronic Acid 1 Single 1.57294 
22 C20- 021 Hyaluronic Acid 1 Single 1.42935 
23 C19- C22 Hyaluronic Acid 1 Single 1.53752 
24 C22- 023 Hyaluronic Acid 1 Single 1.42903 
25 C17-024 Hyaluronic Acid 1 Single 1.43032 
26 024- C25 Hyaluronic Acid 1 Single 1.43136 
27 C16- N26 Hyaluronic Acid 1 Single 1.45817 
28 N26- C27 Hyaluronic Acid 1 Single 1.34361 
29 C27- C28 Hyaluronic Acid 1 Single 1.49999 
30 C27- 029 Hyaluronic Acid 2 Double 1.23771 
31 Cl- Hl Hyaluronic Acid 1 Single 1.09 
32 C2- H2 Hyaluronic Acid 1 Single 1.09 
33 C3- H3 Hyaluronic Acid 1 Single 1.09 
34 C4-H4 Hyaluronic Acid 1 Single 1.09 
35 C6-H5 Hyaluronic Acid 1 Single 1.09 
36 09- H6 Hyaluronic Acid 1 Single 1.05003 
37 Cll- H7 Hyaluronic Acid 1 Single 1.08996 
38 Cll- H8 Hyaluronic Acid I Single 1.09003 
39 Cll- H9 Hyaluronic Acid 1 Single 1.09003 
40 012- HlO Hyaluronic Acid 1 Single 1.05003 
41 013-Hll Hyaluronic Acid 1 Single 1.05003 
42 CIS- H12 Hyaluronic Acid 1 Single 1.09 
43 Cl6- H13 Hyaluronic Acid 1 Single 1.09 
44 Cl7- Hl4 Hyaluronic Acid 1 Single 1.09 
45 Cl9- HIS Hyaluronic Acid 1 Single 1.09 
46 C20- H16 Hyaluronic Acid 1 Single 1.09 
47 021- Hl7 Hyaluronic Acid 1 Single 1.05003 
48 C22- Hl8 Hyaluronic Acid 1 Single 1.09 
49 C22- Hl9 Hyaluronic Acid I Single 1.09 
50 023- H20 Hyaluronic Acid 1 Single 1.05003 
51 C25- H21 Hyaluronic Acid I Single 1.08996 
52 C25- H22 Hyaluronic Acid 1 Single 1.09003 
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No Name Parent Order Type Length 
53 C25- H23 Hyaluronic Acid 1 Single 1.09003 
54 N26- H24 Hyaluronic Acid 1 Single 1.07 
55 C28- H25 Hyaluronic Acid 1 Single 1.08996 
56 C28- H26 Hyaluronic Acid 1 Single 1.09003 
57 C28- H27 Hyaluronic Acid 1 Single 1.09003 
Figure 4.4 shows modeling of Hyaluronic Acid with each atom numbered. Hyaluronic 
Acid structure shows the total measurements of bond length = 57 with average bond 
length= 1.280556.The table 4.7 shows modeling of Hyaluronic Acid, the total number of 
atom is 56 with molecular composition C: 0.452, H: 0.064, N: 0.033, 0: 0.451 and net 
formal charge =0. 
4.1.2 Multi-molecular Modeling 
(1) Cisplatin- Hyaluronic Acid(HA) 
Figure 4.5 Molecular modeling of Cisplatin- Hyaluronic Acid (HA) 
Table 4. 9: Bond and length of Cisplatin- Hyaluronic Acid (HA) 
No Name Parent Order Type Length 
1 Cl- C2 Hyaluronic Acid 1 Single 1.6502 
2 C2-C3 Hyaluronic Acid 1 Single 1.43317 
3 C3 -C4 Hyaluronic Acid 1 Single 1.64526 
4 C4- 05 Hyaluronic Acid 1 Single 1.52019 
5 05- C6 Hyaluronic Acid 1 Single 1.31957 
6 C6- Cl Hyaluronic Acid 1 Single 1.587 
7 C6- C7 Hyaluronic Acid 1 Single 1.48824 
8 C7 -08 Hyaluronic Acid 2 Double 1.23553 
9 C7- 09 Hyaluronic Acid-Cisplatin 1 Single 1.38546 
10 Cl- 010 Hyaluronic Acid 1 Single 1.45754 
11 010- Cll Hyaluronic Acid 1 Single 1.44214 
12 C2- 012 Hyaluronic Acid 1 Single 1.42787 
13 C3- 013 Hyaluronic Acid 1 Single 1.42555 
14 C4- 014 Hyaluronic Acid 1 Single 1.45316 
15 014- C15 Hyaluronic Acid 1 Single 1.45878 
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No Name Parent Order Type Length 
16 CIS- Cl6 Hyaluronic Acid 1 Single 1.45045 
17 Cl6- Cl7 Hyaluronic Acid 1 I Single 1.66735 
18 Cl7- 018 Hyaluronic Acid 1 Single 1.522 
19 018- Cl9 Hyaluronic Acid 1 Single 1.31852 
20 Cl9- CZO Hyaluronic Acid I Single 1.57794 
21 CZO- CIS Hyaluronic Acid 1 Single 1.62192 
22 czo- 021 Hyaluronic Acid 1 Single 1.43608 
23 Cl9- C22 Hyaluronic Acid 1 Single 1.5295 
24 C22- 023 Hyaluronic Acid 1 Single 1.4268 
25 Cl7- 024 Hyaluronic Acid 1 Single 1.42985 
26 024- C25 Hyaluronic Acid 1 Single 1.42981 
27 Cl6- N26 Hyaluronic Acid 1 Single 1.46658 
28 N26- C27 Hyaluronic Acid 1 Single 1.34449 
29 C27- C28 Hyaluronic Acid 1 Single 1.49545 
30 C27- 029 Hyaluronic Acid 2 Double 1.23692 
31 Cl-Hl Hyaluronic Acid 1 Single 1.09844 
32 C2-H2 Hyaluronic Acid 1 Single 1.09904 
33 C3 -H3 Hyaluronic Acid 1 Single 1.10309 
34 C4-H4 Hyaluronic Acid 1 Single 1.09827 
35 C6-H5 Hyaluronic Acid 1 Single 1.10369 
36 Cll- H7 Hyaluronic Acid 1 Single 1.09886 
37 Cll- H8 Hyaluronic Acid 1 Single 1.08686 
38 Cll- H9 Hyaluronic Acid 1 Single 1.09939 
39 012- HlO Hyaluronic Acid 1 Single 0.979642 
40 013-Hll Hyaluronic Acid 1 Single 0.988695 
41 CIS- H12 Hyaluronic Acid 1 Single 1.09635 
42 C16- Hl3 Hyaluronic Acid 1 Single 1.10112 
43 C17-Hl4 Hyaluronic Acid 1 Single 1.0964 
44 C19-H15 Hyaluronic Acid 1 Single 1.10274 
45 CZO -H16 Hyaluronic Acid 1 Single 1.09685 
46 021-H17 Hyaluronic Acid 1 Single 0.986659 
47 C22- H18 Hyaluronic Acid 1 Single 1.09906 
48 C22- Hl9 Hyaluronic Acid 1 Single 1.09898 
49 023 -H20 Hyaluronic Acid 1 Single 0.989383 
50 C25- H21 Hyaluronic Acid I Single 1.09905 
51 C25 -H22 Hyaluronic Acid 1 Single 1.0995 
52 C25 -H23 Hyaluronic Acid 1 Single 1.09936 
53 N26- H24 Hyaluronic Acid 1 Single 0.993188 
54 C28 -H25 Hyaluronic Acid 1 Single 1.0994 
55 C28- H26 Hyaluronic Acid I Single 1.09956 
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No Name Parent Order Type Length 
56 C28- H27 Hyaluronic Acid 1 Single 1.09944 
57 N1 - Pt2 Cisplatin 1 Single 2.00346 
58 Pt2- Cl4 Cisplatin 1 Single 2.30115 
59 Pt2- N5 Cisplatin 1 Single 2.00314 
60 N5 -H6 Cisplatin 1 Single 1.0295 
61 N5 -H7 Cisplatin 1 Single 1.03012 
62 N5 -H8 Cisplatin 1 Single 1.02932 
63 N1-H9 Cisplatin 1 Single 1.03098 
64 N1- H10 Cisplatin 1 Single 1.02911 
65 N1 - H11 Cisplatin 1 Single 1.02942 
66 Pt2- 09 Cisplatin 1 Single 1.95687 
Figure 4.5 shows modeling of Cisplatin- Hyaluronic Acid (HA) with each atom 
numbered. Cisplatin- Hyaluronic Acid (HA) structure shows the total measurements of 
bond length = 66 with average bond length = 1.308173. HA is found naturally inside 
human body, highly viscous and a versatile polymer. Due to its biocompatibility and 
hydrophilic nature, the problem of poor solubility of naturally occurring, cytotoxic and 
hydrophobic anticancer agents can be overcome which open up avenues for anticancer 
agent delivery A glycoprotein CD44 receptor, normally overexpressed in cancer cells, 
can serve as a major receptor protein for HA (Gul-e-Saba et al., 2011). Cisplatin, 
classified as an alkylating agent, is the ftrst platinum-based anticancer drug. It inhibits 
synthesis or multiplication of host DNA by formation of DNA adducts that result in cell 
death (Gul-e-Saba et al., 2011). Inside the cells, HA undergoes degradation and drug will 
be released (Gul-e-Saba eta!., 2011). Released cisplatin undergoes hydrolysis, producing 
the highly reactive charged platinum complex [Pt (NH3)2CIH20] + in the ftrst step 
hydrolysis with the substitution of one Cl-atom with water molecule. Second step 
hydrolysis produced highly oxidized form of cisplatin by substitution of second Cl-atom 
with water molecule. This Pt complex interacts with DNA through the N7 atom of either 
a guanine or adenine base. Further hydrolysis displaces the remaining chloride ligand, 
and the platinum can bind to a second nucleotide base. The cisplatin-DNA adduct is 
recognized by a high mobility group (HMG)-domain protein, among other DNA repair 
proteins, which binds tightly to the complex. The adduct causes destacking of the 
nucleotide bases, resulting in the DNA helix becoming kinked (Trzaska, 2005). 
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(2) PLGA-PEG-bis-amine- Hyaluronic Acid(HA) 
Figure 4.6 Molecular modeling ofPLGA-PEG-biS-amrne- Hyaluronic Acid (HA) 
Table 4.10: Bond and length ofPLGA-PEG-biS-amrne- Hyaluromc Acid (HA) 
No. Name Parent Order Type Length (A) 
1 Cl- C2 Hyaluronic Acid 1 Single 1.65421 
2 C2- C3 Hyaluronic Acid 1 Single 1.43798 
3 C3- C4 Hyaluronic Acid I Single 1.64219 
4 C4- 05 Hyaluronic Acid 1 Single 1.51794 
5 05 - C6 Hyaluronic Acid 1 Single 1.32966 
6 C6 - C1 Hyaluronic Acid 1 Single 1.58803 
7 C6- C7 Hyaluronic Acid 1 Single 1.54045 
8 C7 - 08 Hyaluronic Acid 2 Double 1.23577 
9 C1-010 H luronic Acid 1 Single 1.45877_ 
1-- - -
10 010 - Cll Hyaluronic Acid 1 Single 1.44341 
11 C2- 012 Hyaluronic Acid I Single 1.4279 
12 C3- 013 Hyaluronic Acid 1 Single 1.42562 
13 C4- 014 Hyaluronic Acid 1 Single 1.45506 
14 014- C15 Hyaluronic Acid I Single 1.46159 
15 C15-C16 Hyaluronic Acid 1 Single 1.45083 
16 C16-C17 Hyaluronic Acid 1 Single 1.66793 
17 C17 - 018 Hyaluronic Acid 1 Single 1.52218 
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No. Name Parent Order Type Length( A) 
18 018- Cl9 Hyaluronic Acid 1 Single 1.31802 
19 Cl9- C20 Hyaluronic Acid 1 Single 1.57516 
20 C20- CIS Hyaluronic Acid 1 Single 1.61966 
21 C20- 021 Hyaluronic Acid 1 Single 1.43594 
22 Cl9- C22 Hyaluronic Acid 1 Single 1.53067 
23 C22- 023 Hyaluronic Acid 1 Single 1.42623 
24 Cl?-024 Hyaluronic Acid 1 Single 1.42983 
25 024- C25 Hyaluronic Acid 1 Single 1.42979 
26 Cl6- N26 Hyaluronic Acid 1 Single 1.46651 
27 N26- C27 Hyaluronic Acid 1 Single 1.34448 
28 C27- C28 Hyaluronic Acid 1 Single 1.49547 
29 C27- 029 Hyaluronic Acid 2 Double 1.2369 
30 Cl- Hl Hyaluronic Acid 1 Single 1.0983 
31 C2-H2 Hyaluronic Acid 1 Single 1.09903 
32 C3 -H3 Hyaluronic Acid 1 Single 1.10268 
33 C4-H4 Hyaluronic Acid 1 Single 1.09819 
34 C6-H5 Hyaluronic Acid 1 Single 1.10187 
35 C11- H7 Hyaluronic Acid 1 Single 1.09891 
36 C11- H8 Hyaluronic Acid 1 Single 1.08611 
37 C11- H9 Hyaluronic Acid I Single 1.099 
38 012- H10 Hyaluronic Acid 1 Single 0.979109 
39 013-H11 Hyaluronic Acid 1 Single 0.988776 
40 CIS- Hl2 Hyaluronic Acid 1 Single 1.09638 
41 Cl6- H13 Hyaluronic Acid 1 Single 1.10112 
42 Cl7- Hl4 Hyaluronic Acid 1 Single 1.09635 
43 Cl9- HIS Hyaluronic Acid I Single 1.10271 
44 C20- Hl6 Hyaluronic Acid I Single 1.09509 
45 021- Hl7 Hyaluronic Acid 1 Single 0.986539 
46 C22- Hl8 Hyaluronic Acid 1 Single 1.10032 
47 C22- Hl9 Hyaluronic Acid 1 Single 1.09901 
48 023- H20 Hyaluronic Acid 1 Single 0.989312 
49 C25- H21 Hyaluronic Acid 1 Single 1.09903 
50 C25 -H22 Hyaluronic Acid 1 Single 1.09954 
51 C25- H23 Hyaluronic Acid 1 Single 1.0993 
52 N26- H24 Hyaluronic Acid 1 Single 0.993187 
53 C28- H25 Hyaluronic Acid 1 Single 1.09942 
54 C28- H26 Hyaluronic Acid 1 Single 1.09951 
55 C28- H27 Hyaluronic Acid 1 Single 1.09947 
56 Nl- C7 PEG-HA 1 Single 1.34936 
57 Nl- C2 PEG-his amine I Single 1.43977 
58 C2- C3 PEG-his amine I Single 1.53534 
59 C3- 04 PEG-his amine 1 Single 1.42819 
60 04- cs PEG-his amine 1 Single 1.42779 
61 CS- C6 PEG-his amine 1 Single 1.53802 
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No. Name Parent Order Type Length (A) 
62 C6- N7 PEG-bis amine 1 Single 1.43419 
63 N7- C8 PEG-bis amine 1 Single 1.39519 
64 C8- 09 PEG-bis amine 2 Double 1.23641 
65 N1- H40 PEG-bis amine 1 Single 1.07 
66 C2 -H41 PEG-bis amine 1 Single 1.09 
67 C2- H42 PEG-bis amine 1 Single 1.09 
68 C3 -H43 PEG-bis amine 1 Single 1.09 
69 C3- H44 PEG-bis amine 1 Single 1.09 
70 C5- H45 PEG-bis amine 1 Single 1.09 
71 C5- H46 PEG-bis amine 1 Single 1.09 
72 C6- H47 PEG-bis amine 1 Single 1.09 
73 C6 -H48 PEG-bis amine 1 Single 1.09 
74 N7 -H49 PEG-bis amine 1 Single 1.07 
75 C8- 01 PLGA-PEG 1 Single 1.39224 
76 01- C2 PLGA 1 Single 1.43024 
77 C2- C3 PLGA 1 Single 1.49798 
78 C3- 04 PLGA 1 Single 1.39185 
79 04 -C5 PLGA 1 Single 1.42868 
80 C5- C6 PLGA 1 Single 1.49864 
81 C6- 07 PLGA 1 Single 1.4095 
82 07- C8 PLGA 1 Single 1.44536 
83 C8- C9 PLGA 1 Single 1.49838 
84 C9- 010 PLGA 1 Single 1.40994 
85 010- Cll PLGA 1 Single 1.44508 
86 Cll- C12 PLGA I Single 1.50032 
87 C3- 013 PLGA 2 Double 1.23636 
88 C6- 014 PLGA 2 Double 1.23702 
89 C12- 015 PLGA 2 Double 1.23615 
90 Cll- C16 PLGA 1 Single 1.55065 
91 C8- Cl7 PLGA 1 Single 1.55089 
92 C9- 018 PLGA 2 Double 1.23706 
93 C2 -H27 PLGA 1 Single 1.09 
94 C2 -H28 PLGA 1 Single 1.09 
95 C5- H29 PLGA 1 Single 1.09 
96 C5- H30 PLGA 1 Single 1.09 
97 C8- H31 PLGA 1 Single 1.09 
98 C11- H32 PLGA 1 Single 1.09 
99 C12- H33 PLGA 1 Single 1.09 
100 C16- H34 PLGA 1 Single 1.08996 
I 01 C16- H35 PLGA 1 Single 1.09003 
102 C16- H36 PLGA 1 Single 1.09003 
103 C17- H37 PLGA I Single 1.08995 
104 C17- H38 PLGA 1 Single 1.09003 
105 Cl7- H39 PLGA I Single 1.09003 
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Figure 4.6 shows modeling ofPLGA-PEG-bis-amine- Hyaluronic Acid (HA) with each 
atom numbered. PLGA-PEG-bis-amine- Hyaluronic Acid (HA) structure shows the total 
measurements of bond length= 105 with average bond length= 1.274163. The PLGA 
polymer had several advantages like good mechanical properties, low immunogenicity 
and toxicity, excellent biocompatibility and predictable biodegradation kinetics. The wide 
acceptance of the lactide/glycolide polymers as suture materials made them attractive 
candidates for biomedical applications like ligament reconstruction, tracheal replacement, 
surgical dressings, vascular grafts and nerve, dental and fracture repairs (Lewis et 
al.,1990; Visscher eta!., 1988).The PEG-his-amine act as the spacer arm to connect the 
PLGA together with HA. HA-conjugates often target CD44 glycoprotein, a receptor on 
cancer cells. CD44 has been suggested as one of the important surface markers for both 
normal stem cells and cancer stem cells (Al-Haj eta!., 2003). HA interactions with CD44 
mediate at least three important physiological processes - signal transduction, assembly 
of pericellular matrices, and receptor-mediated internalization (Toole, 2001; Knudson et 
a!., 2002) Nanoparticulate delivery systems strategy may allow a controlled release of the 
drug and a high targeting selectivity on tumor cells, increasing drug cytotoxicity and 
decreasing its undesirable side effects (Serafino et a!., 2011 ). 
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(3) Cisplatin-PLGA-PEG-bis-amine- Hyaluronic Acid(HA) 
Figure 4.7 Spherical structure ofPLGA-PEG-HA surrounding Cisplatin molecule. 
Poor water solubility has always been one of the most fundamental problems in drug 
delivery (Pate~ 2011). It is estimated that around 40% of drugs in the pipeline cannot be 
delivered through the preferred route or in some cases, at all, owing to poor water 
solubility (Salata, 2004). Bioconjugates of low molecular weight HA with cytotoxic 
agents is designed to improve solubility of the cytotoxic agent and facilitate its 
intravenous administration (Brekke & Gubbe, 2008). The mechanical strength, swelling 
behavior, capacity to undergo hydrolysis and, subsequently, the biodegradation rate are 
directly influenced by the crystallinity of the PLGA polymer. The resultant crystallinity 
of the PLGA copolymer is dependent on the type and the molar ratio of the individual 
monomer components (lactide and glycolide) in the copolymer chain. PLGA polymers 
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containing a 50:50 ratio of lactic and glycolic acids are hydrolyzed much faster than those 
containing a higher proportion of either of the two monomers (Gilding & Reed, 1979; Li 
& McCarthy, 1999).PGA is highly crystalline because it lacks the methyl side groups of 
the PLA. Lactic acid is more hydrophobic than glycolic acid and, therefore, lactide-rich 
PLGA co-polymers are less hydrophilic, absorb less water and, subsequently, degrade 
more slowly (Schliecker et al., 2003; Makino et al., 1985). Cisplatin as a free drug is 
sparingly soluble in water, conjugation to PLGA-PEG HA not only further increases its 
solubility, but more importantly it enhances the chances to reach the cancer site. As 
CD44 is over expressed in cancer cells, malignant cells with high metastatic activities 
often exhibit enhanced binding and uptake of HA With intrinsic cell specific binding 
capacity and strong affinity to cell-specific surface markers such as CD44 (Maeda et a!., 
1992) and Nanoparticulate delivery systems strategy may allow a controlled release of 
the drug and a high targeting selectivity on tumor cells, increasing drug cytotoxicity and 
decreasing its undesirable side effects (Serafino et al., 2011). Cisplatin-PLGA-PEG-HA 
interaction can be further modelled for CD-44 target and this could pave the way for 





• Simulation studies are provide the better understanding of polymeric conjugate 
structure and it role in delivery of drug to targeted side in human body. The 
molecular 3D structural modeling ofCisplatin, PLGA, PEG, HA and conjugated 
molecular 3D Structures Cisplatin conjugated HA and PLGA-PEG-HA 
successfully completed using Discovery Studio 2.5. 
• Besides this Nano spherical structure of PLGA-PEG-HA surrounding cisplatin 
molecule also generated to create the concept of Nano polymeric drug delivery 
system (PDDS). 
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